Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Sales (2022 - 2025)

Historic Return on Sales for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.1%.

  • Kiniksa Pharmaceuticals International's Return on Sales rose 2200.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 2800.0%. This contributed to the annual value of 0.1% for FY2024, which is 1200.0% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Return on Sales of 0.1% as of Q3 2025, which was up 2200.0% from 0.11% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Return on Sales' 5-year high stood at 2.26% during Q3 2022, with a 5-year trough of 5.39% in Q2 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Return on Sales value was 0.21% (recorded in 2023), while the average stood at 0.62%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Return on Sales soared by 47900bps in 2022, and later tumbled by -24700bps in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Return on Sales stood at 2.35% in 2021, then soared by 75bps to 0.6% in 2022, then grew by 1bps to 0.59% in 2023, then surged by 88bps to 0.07% in 2024, then skyrocketed by 241bps to 0.1% in 2025.
  • Its last three reported values are 0.1% in Q3 2025, 0.11% for Q2 2025, and 0.06% during Q1 2025.